Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galapagos : completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease - Form 6-K

11/29/2021 | 06:11am EST

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

Mechelen, Belgium; 22 November 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).

MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737 (NCT04578548). The drug candidate or placebo is administered for 52 weeks, followed by an open-label extension period of 52 weeks, in 66 ADPKD patients with rapidly progressing disease. Patients are randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the effect on growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary objectives include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial was conducted in 7 countries in Europe.

GLPG2737 is a CFTR1 inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and kidney enlargement for patients with ADPKD.

Galapagos expects topline results from the MANGROVE Phase 2 trial in the first half of 2023.

"We thank the ADPKD community for participating in the MANGROVE Phase 2 trial with GLPG2737," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. "Polycystic kidney disease patients have a real need for new therapy options. We hope to learn in 2023 from this trial what CFTR modulation may be able to achieve against ADPKD, in our mission to bring new medicines to kidney disease patients."

Autosomal dominant polycystic kidney disease affects approximately 12.5 million people worldwide and is the fourth leading cause of kidney failure today.2 Typically with this disease, both kidneys enlarge with fluid-filled cysts, leading to kidney failure for approximately half of patients by the age of 60 and requiring dialysis and possibly kidney transplantation.3 Patients may also suffer from hypertension, abdominal pain, kidney infections, cyst ruptures, bleeding, and other symptoms impacting quality of life. Other organs may be affected as well. Treatment is aimed at relieving symptoms and controlling the accompanying hypertension. Currently, only one therapy (tolvaptan) is available to slow down the progression of cyst development and renal insufficiency; however, not all patients tolerate this therapy.4

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information is available at www.glpg.com.


Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

Evelyn Fox
Director Executive Communications
+31 65 3591 999

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG2737 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG2737 due to safety or efficacy concerns or other reasons), Galapagos' reliance on collaborations with third parties, and that Galapagos' estimations regarding its GLPG2737 development program, regarding the potential value of CFTR inhibition as a mechanism to treat ADPKD, and regarding the commercial potential of GLPG2737, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management's current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

1 Cystic Fibrosis Transmembrane Conductance Regulator
2 Chebib F.T., Torres V.E. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis. May 2016, 67 (5) 792-810
3 Parfrey P.S., Bear J.C., Morgan J., Cramer B.C., McManamon P.J., Gault M.H., et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323(16):1085-90
4 Chebib F.T., Perrone R.D., Chapman A.B., Dahl N.K., Harris P.C., Mrug M., et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. JASN. October 2018, 29 (10) 2458-2470


Galapagos NV published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 11:09:34 UTC.

ę Publicnow 2021
All news about GALAPAGOS NV
01/27Health Care Outperform Amid Fading Thursday Markets
01/27Health Care Stocks Still Outperforming Amid Fading Thursday Markets
01/27Galapagos Names Former Johnson & Johnson Executive Paul Stoffels CEO; Shares Soar
01/27GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K
01/26Galapagos Appoints Former Johnson & Johnson Exec to Succeed Retiring CEO
01/26Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
01/26GALAPAGOS : creates new subscription right plan - Form 6-K
01/26Galapagos creates new subscription right plan
01/26Galapagos appoints Paul Stoffels as Chief Executive Officer
01/26Galapagos NV Appoints Paul Stoffels as Chief Executive Officer
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Sales 2021 485 M 540 M 540 M
Net income 2021 -182 M -203 M -203 M
Net cash 2021 3 976 M 4 434 M 4 434 M
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 3 756 M 4 189 M 4 189 M
EV / Sales 2021 -0,45x
EV / Sales 2022 0,42x
Nbr of Employees 1 319
Free-Float 74,5%
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 9
Last Close Price 57,30 €
Average target price 55,56 €
Spread / Average Target -3,04%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj Bhikhu Parekh Chairman
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV16.42%4 189
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592